Clara Domingo‐Vila

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Leticia Monin, Adam G. Laing, Miguel Muñoz‐Ruiz et al. · The Lancet Oncology · 2021 · 612 citations · Full text

Veterinary Medicine, Immunology, Oncology +14

The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

Satveer K. Mahil, Katie Bechman, Antony Raharja et al. · The Lancet Rheumatology · 2021 · 176 citations · Full text

Medicine, Dermatology, Immunology +17

Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines

Leticia Monin, Adam G. Laing, Miguel Muñoz‐Ruiz et al. · medRxiv · 2021 · 61 citations · Full text

Veterinary Medicine, Immunology, Oncology +17

Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study

Satveer K. Mahil, Katie Bechman, Antony Raharja et al. · QUT ePrints (Queensland University of Technology) · 2022 · 53 citations

Life Sciences, Immunology, Pharmacology +16

Type 1 diabetes can present before the age of 6 months and is characterised by autoimmunity and rapid loss of beta cells

Matthew B. Johnson, Kashyap Patel, Elisa De Franco et al. · Diabetologia · 2020 · 44 citations · Full text

Medicine, Genetics, Pediatrics +17